Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 18
Submit an article Journal homepage
223
Views
10
CrossRef citations to date
0
Altmetric
Drug Evaluation

Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting

Simon JP Van Belle University Hospital Ghent, Department of Medical Oncology, De Pintelaan 185, 9000 Ghent, Belgium +32 9 332 4298; +32 9 332 6287; [email protected]
, MD PhD &
Veronique Cocquyt University Hospital Ghent, Department of Medical Oncology, De Pintelaan 185, 9000 Ghent, Belgium +32 9 332 4298; +32 9 332 6287; [email protected]
, MD PhD
Pages 3261-3270 | Published online: 28 Nov 2008

Bibliography

  • Coates A, Abraham S, Kaye SB, et al. On the receiving end – patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8
  • Grunberg SM, Deuson R, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 2004;100:2226-68
  • Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97:2880-6
  • Cohen L, De Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting – incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503
  • Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472-8
  • Wang SC, Borison HL. The vomiting center: a critical experimental analysis. Arch Neurol Psychiatry 1950;63:928-41
  • Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111(Suppl 8A):106-112
  • Miller AD, Wilson VJ. ‘Vomiting center’ reanalyzed: an electrical stimulation study. Brain Res 1983;270:154-8
  • Miller AD, Grelot S. Neural control of respiratory muscle activation during vomiting. In: Miller AD, Bianchi AL, Bishop BP, editors, Neural control of the respiratorymuscles, Boca Raton, FL: CRC Press; 1997. p. 239-48
  • Fukuda H, Koga T. Non-respiratory neurons in the Bötzinger complex exhibiting appropriate firing patterns to generate the emetic act in dogs. Neurosci Res 1992;14:180-94
  • Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema to the pattern generator for the emetic act in dogs. Neurosci Res 1992;14:166-79
  • Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94
  • Higgins GA, Kilpatrick GJ, Bunce KT, et al. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 1989;97:247-55
  • Carpenter DO, Briggs DB, Strominger N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol 1983;3:113-26
  • Zagon A, Totterdell S, Jones RS. Direct projections from the ventrolateral medulla oblongata to the limbic forebrain: anterograde and retrograde tract-tracing studies in the rat. J Comp Neurol 1994;340:445-68
  • Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006;2(Suppl 1):3-8
  • Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 2005;13:80-4
  • Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-84
  • Hesketh PJ, Van Belle S, Aapro M, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 2003;39:1074-80
  • Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res 1984;11:277-81
  • Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1998;32:1-49
  • Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 2007;101:143-50
  • Herrstedt J, Roila F. ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2008;19(Suppl 2ii):10-2
  • Available from: http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update.pdf
  • Roila F, Hesketh PJ, Herrstedt J. Antiemetic subcommittee of the multinational association of supportive care in cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international antiemetic consensus conference. Ann Oncol 2006;17:20-8
  • Rolski J, Ramlau R, Dediu M, et al. Randomized Phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) [abstract 8513]. J Clin Oncol ASCO Annual Meeting Proceedings 24;2006
  • Aziz Z, Arpornwirat W, Herrstedt J, et al. Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC) [abstract 20512]. J Clin Oncol. ASCO Annual Meeting Proceedings 26;2008
  • Herrstedt J, Grunberg S, Rolski J, et al. Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC) [abstract 9549]. J Clin Oncol. ASCO Annual Meeting Proceedings 26;2008
  • Grunberg S, Aziz Z, Shaharyar A, et al. Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) [abstract 9540]. J Clin Oncol. ASCO Annual Meeting Proceedings 26;2008
  • Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther 2006;3:140-2
  • Brocco M, Dekeyne A, Mannoury La Cour C, et al. Cellular and behavioural profile of the novel, selective neurokinin(1) receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol [Epub 2008 Jul 24]
  • Hoffmann-Emery F, Hilpert H, Scalone M, Waldmeier P. Efficient synthesis of novel NK1 receptor antagonists: selective 1,4-addition of grignard reagents to 6-chloronicotinic acid derivatives. J Org Chem 2006;71:2000-8
  • Hickman MA, Cox SR, Mahabir S, et al. Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats. J Vet Pharmacol Ther 2008;31:220-9
  • Watanabe Y, Okamoto M, Ishii T, et al. Long-lasting anti-emetic effect of T-2328, a novel NK(1) antagonist. J Pharmacol Sci 2008;107:151-8
  • Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37:835-42
  • Van Belle S, Lichinitser MR, Navari RM, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032-41
  • Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007;47:834-40
  • Rx List, The Internet Drug Index. Available from: http://www.rxlist.com/emend-drug.htm [last accessed 29 October 2008]
  • Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60:533-46
  • Snider RM, Constantine JW, Lowe JA 3rd, et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991;251:435-7
  • Knox AP, Strominger NL, Battles AH, Carpenter DO. Behavioral studies of emetic sensitivity in the ferret. Brain Res Bull 1993;31:477-84
  • Bountra C, Bunce K, Dale T, et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993;249:R3-4
  • Watson JW, Gonsalves SF, Fossa AA, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 1995;115:84-94
  • Tattersall FD, Rycroft W, Francis B, et al. Tachykinins NK-1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996;35:1121-9
  • Kris MG, Radford JE, Pizzo BA, et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997;89:817-8
  • Hale JJ, Mills SG, MacCoss M, et al. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 1998;41:4607-14
  • Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000;39:652-63
  • Huskey SE, Dean BJ, Bakhtiar R, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos 2003;31:785-91
  • Huskey SE, Dean BJ, Doss GA, et al. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos 2004;32:246-58
  • Navari RM, Carides AD, Gertz BJ, et al. Prevention of cisplatin-induced emesis by a neurokinin-1 receptor antagonist. N Engl J Med 1999;340:190-5
  • Majumdar AK, Howard L, Goldberg MR, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46:291-300
  • Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215-23
  • Mc Crea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24
  • Blum RA, Majumdar A, Mc Crea J, et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19
  • Feuring M, Lee Y, Orlowski LH, et al. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003;43:912-7
  • Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55:609-16
  • Shah AK, Hunt TL, Gallagher SC, Cullen MT, Jr. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005;21:595-601
  • Li SX, Pequignot E, Panebianco D, et al. Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers. J Clin Pharmacol 2006;46:792-801
  • Loos WJ, De Wit R, Freedman SJ, et al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59:407-12
  • Depré M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61:341-6
  • Chemotherapy side effects information at emend.com. Available from: http://www.emend.com/aprepitant/emend/consumer/index.jsp [last accessed 29 October 2008]
  • De Jonge ME, Huitema AD, Holtkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56:370-8
  • Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300
  • Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67
  • Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9
  • Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
  • Gralla RJ, De Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer 2005;104:864-8
  • De Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11
  • De Wit R, Herrstedt J, Rapoport B, et al. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled Phase III clinical trials. Eur J Cancer 2004;40:403-10
  • Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
  • Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-85
  • Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112:2080-7
  • Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005;45:857-60
  • Hesketh PJ, Younger J, Sanjay R, et al. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide (AC) [abstract 8618]. J Clin Oncol 2006 ASCO Annual Meeting Proceedings 24
  • Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two Phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14:354-60
  • Alvaro G, Di Fabio R. Neurokinin 1 receptor antagonists–current prospects. Curr Opin Drug Discov Devel 2007;10:613-21
  • Ranga K, Krishnan R. Clinical experience with substance P receptor (NK1) antagonists in depression. J Clin Psychiatry 2002;63(Suppl 11):25-9
  • Kramer MS, Winokur A, Kelsey J, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 2004;29:385-92
  • Keller M, Montgomery S, Ball W, et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006;59:216-23
  • Green SA, Alon A, Ianus J, et al. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 2006;176:2535-40
  • Lim R, Morrill JM, Prushik SG, et al. An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraabdominal adhesions when administered intraperitoneally, but not orally. J Gastrointest Surg [Epub 2008 Aug 16]
  • Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008;27:609-15
  • Diemunsch P, Apfel C, Gan TJ, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin 2007;23:2559-65
  • Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007;18:808-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.